Cenova Capital
赛纳资本
Cenova Capital (千骥资本) is a Chinese healthcare-focused venture investor that shows up in elsewhere's corpus chiefly as a backer of digital-health and biotech deals. Its longest-running position is in local medical-services platform WeiMai: Cenova led one of WeiMai's early rounds in 2018 and then followed on through the company's $100M 2019 round, its 2020 Series C+ , and again in the RMB 200M Series D reported in January 2025 — partner Shen Xiaoyin framed the thesis as investing in "care of patients," betting WeiMai's local doctor-patient trust links would become a default for local care . Beyond WeiMai, it was the sole investor in soluble microneedle drug-delivery company Youwei Biology's near-RMB-100M Series B in 2022 , and joined OrbiMed, Lilly Asia Ventures and others in Pulnovo Medical's tens-of-millions-USD round that same year . The corpus doesn't carry a founding-date or fund-size profile of the firm itself — what it shows is a consistent healthcare specialist, comfortable both leading early rounds and riding alongside larger syndicates.
AI-generated — may contain errors, please verify.
Coverage
From Two Rounds in Six Months to a $400M Series D: 10 Companies Announce New Funding | FreeS Family Funding News Vol.24
Looking forward to working alongside more outstanding founders.
Yunqi Capital Quarterly | Spring Winds Ask Nothing of the Traveler; We Chart Our Own Course
A Closer Look at Yunqi Capital's Recent Moves
Yunqi Capital | "Weichong Semiconductor" Closes Tens of Millions in Series A+ Funding
Recently, **Weichong Semiconductor**, a Yunqi Capital portfolio company specializing in semiconductor metrology and inspection equipment, **closed a Series A+ round of tens of millions of RMB**. The round was led by Jinyu Maowu, Optics Valley Semiconductor Industry Investment, and Saina Capital. The funds will be used for R&D, market expansion, and team building.
